On Monday, Shares of SBA Communications Corporation (NASDAQ:SBAC), subtract -2.13% and closed at $96.91 in the last trading session. The last trading range of the stock ranges between $95.50 and $98.56. SBA Communications Corporation (SBAC) (“SBA” or the “Company”) recently stated results for the quarter ended September 30, 2016.
“The third quarter was another solid quarter for SBA,” commented Jeffrey A. Stoops, President and Chief Executive Officer. “Organic leasing demand was steady, consistent with both the type and amount of customer activity practiced all year. Amendment activity in the U.S. was very strong, with our customers adding to or modifying existing macro sites to refarm 2G and 3G uses to 4G LTE or to add new spectrum to their networks. In our international markets, customer activity was more balanced between new macro sites and additions or modifications to existing macro sites. Our Outlook for the Fourth Quarter of 2016 assumes customer activity remains materially the same as we have practiced during the first three quarters of the year. We executed very well in the third quarter, producing once again industry-leading operating margins. We allocated capital in the quarter opportunistically and in our opinion very attractively, spread among portfolio growth, stock repurchases and ground purchases. We ended the quarter within our target leverage range. Finally, we accomplished a refinancing of a material portion of our indebtedness on very favorable terms, substantially reducing our interest costs on that portion of our capital structure. AFFO continues to increase, and our share count continues to decrease. We expect this same trend to continue in the fourth quarter. Our third quarter success in each of these areas, organic growth, operating performance, asset growth, stock repurchases and financing, positively contributes to our long term aim of producing AFFO of $10 or more per share in 2020.”
Ocular Therapeutix Inc (NASDAQ:OCUL), jumped 9.02% and closed at $7.49 in the last trading session. The last trading range of the stock ranges between $6.95 and $7.82. The company’s Market capitalization is $196.50 million with the total Outstanding Shares of 24.88 million. Ocular Therapeutix, Inc. (OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, recently declared positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain. DEXTENZA is a product candidate administered by a physician as a bioresorbable intracanalicular insert and designed for drug release to the ocular surface for up to 30 days.
The trial successfully met its two primary efficacy endpoints for inflammation and pain, achieving statistically noteworthydifferences between the treatment group and the placebo group for the absence of inflammatory cells on day 14 and the absence of pain on day 8, respectively. 52.3%% of patients treated with DEXTENZA showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14, contrast to 31.1% of those receiving the placebo vehicle control punctum plug (p< 0.0001). 79.6% of patients treated with DEXTENZA stated absence of pain in the study eye on day 8, contrast to 61.3% of those receiving the placebo vehicle control punctum plug (p< 0.0001). For clarification of the endpoints, the day of surgery and insertion of DEXTENZA or the placebo is considered to be day .
Banro Corporation (USA)(NYSEMKT:BAA), lost -4.37% and closed at $0.197 in the last trading session. The last trading range of the stock ranges between $0.17 and $0.20.Company stock’s 52-week range is $0.15 – $0.48. Banro Corporation (“Banro” or the “Company”) (NYSE MKT:BAA)(BAA.TO) recently declared its financial and operating results for the third quarter of 2016.
Record revenues in Q3 2016 of $67 million, representing a boost of 75% over Q3 2015 revenues of $39 million. Year-to-date revenues are $174 million, contrast to year-to-date revenues in 2015 of $122 million, a boost of 42%.
Q3 2016 EBITDA of $24 million, representing a boost in EBITDA of over 20% contrast to about $19 million in each of Q3 2015 and Q2 2016. This improvement reflects Namoya’s success in delivering steady-state production levels throughout the third quarter
Q3 2016 merged (combined Twangiza and Namoya) gold production of 53,377 ounces, a boost of 53% from Q3 2015, with a merged cash cost of $734 per ounce.
Namoya achieved record quarterly gold production of 28,190 ounces in Q3 2016 with a cash cost of $740 per ounce, as gold production rose to over 10,000 ounces in September.
YTD 2016 merged (combined Twangiza and Namoya) gold production of 147,242 ounces with a cash cost of $744 per ounce, combined mine site all-in sustaining cost of $876 per ounce, and total all-in sustaining cost of $963 per ounce, in-line with 2016 guidance.